PUBLIC COMPANY
saveNOVARTIS
USupdated 1d ago
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Moderna maintains 10% growth target despite Phase 3 norovirus missModerna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUS…biospace · 17h ago
- GSK pens $110M biological datasets pact with AI biotech RelationGSK is boosting its AI chops with a new deal worth up to $110 million with Relation.fiercebiotech · 2d ago
- Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storeWith so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.biospace · 2d ago
- GSK cost-cutting plan includes global layoffsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ RhapsidoProcessa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.fiercebiotech · 2d ago
- GSK shares rise as $2.5B cost-cutting plan unveiledAs GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.biospace · 3d ago
- Eli Lilly tops new biopharma ranking on launch success, development speedFlush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global bioph…fiercebiotech · 3d ago
- GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyardGSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…fiercebiotech · 3d ago
- Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdleSafety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this sp…biospace · 5d ago
- Anthropic’s life science plans; Novartis CEO on China deals; and moreWelcome back to Endpoints Weekly! We’re gearing up for a busy week of earnings coverage, as Moderna, AstraZeneca, GSK, Bristol Myers Squibb and more are set to report their Q2 results. In the meant…endpoints · 6d ago
comments(0)
5-min edit window · permanent after that